Dedicated to Conquering Heart Failure
A clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases
Acute Myocarditis
Cardiol has received IND authorization from the U.S FDA to conduct a Phase II multi-national trial designed to evaluate the efficacy and safety of CardiolRx™ in acute myocarditis – an important cause of acute and fulminant heart failure and is a leading cause of sudden cardiac death in people less than 35 years of age.
Learn More
Recurrent Pericarditis
Cardiol has received IND authorization from the U.S. FDA to conduct a Phase II open-label pilot study designed to evaluate the tolerance, safety, and disease endpoints of CardiolRx™ in patients with recurrent pericarditis – the most common of pericardial diseases with symptoms that include debilitating chest pain, shortness of breath, and fatigue.
Learn More
Viral Infection and CVD
CardiolRx™ is currently being evaluated in a Phase II/III multi-national study, the LANCER trial, to evaluate its safety and efficacy as a cardioprotective therapy to reduce major cardiorespiratory events and improve symptoms in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, CVD, and to investigate the impact of CardiolRx™ on key cardiac and inflammatory biomarkers.
Learn More
Heart Failure
Cardiol is developing a subcutaneous cannabidiol formulation targeting the inflammation and fibrosis associated with the development and progression of heart failure – a chronic condition estimated to affect 64 million globally and is a leading cause of death and hospitalization, with associated annual healthcare costs in the U.S. alone exceeding $30 billion.
Learn More
LATEST NEWS
All News
Press Release
Cardiol Therapeutics Reports Results of 2022 Annual General Meeting
June 29, 2022
Cardiol Therapeutics Reports Results of 2022 Annual General Meeting
TSX:CRDL NASDAQ:CRDL
